Comparative Pharmacology
Head-to-head clinical analysis: LEVOMILNACIPRAN versus LEVOMILNACIPRAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOMILNACIPRAN versus LEVOMILNACIPRAN HYDROCHLORIDE.
LEVOMILNACIPRAN vs LEVOMILNACIPRAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Serotonin-norepinephrine reuptake inhibitor (SNRI); increases extracellular levels of serotonin and norepinephrine by inhibiting their reuptake into presynaptic neurons.
SNRI; inhibits reuptake of norepinephrine and serotonin, increasing their concentrations in the synaptic cleft.
20 mg orally twice daily, with or without food; may increase to 40 mg twice daily after 7 days based on tolerability.
20 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 9–13 hours), supporting once-daily dosing.
Clinical Note
moderateLevomilnacipran + Desmopressin
"The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin."
Clinical Note
moderateLevomilnacipran + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Levomilnacipran."
Clinical Note
moderateLevomilnacipran + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Levomilnacipran."
Clinical Note
moderateLevomilnacipran + Sulfisoxazole
Terminal elimination half-life is approximately 12 hours (range 10-14 hours). This supports once-daily dosing in major depressive disorder.
Primarily renal excretion: ~58% of the dose excreted unchanged in urine. Minor biliary/fecal elimination: ~18% recovered in feces.
Primarily renal excretion: approximately 58% of the dose is excreted unchanged in urine. Fecal excretion accounts for about 5%.
Category C
Category C
Serotonin-Norepinephrine Reuptake Inhibitor
Serotonin-Norepinephrine Reuptake Inhibitor
"The metabolism of Sulfisoxazole can be decreased when combined with Levomilnacipran."